Department of Cardiovascular Diseases (Y.L., L.D.M., R.L., R.G., A.S.J.), Mayo Clinic, Rochester, MN.
Division of Biomedical Statistics and Informatics (B.R.L.), Mayo Clinic, Rochester, MN.
Circulation. 2022 Jun 7;145(23):1708-1719. doi: 10.1161/CIRCULATIONAHA.122.059235. Epub 2022 May 10.
There are good data to support using a single high-sensitivity cardiac troponin T (hs-cTnT) below the limit of detection of 5 ng/L to exclude acute myocardial infarction. Per the US Food and Drug Administration, hs-cTnT can only report to the limit of quantitation of 6 ng/L, a threshold for which there are limited data. Our goal was to determine whether a single hs-cTnT below the limit of quantitation of 6 ng/L is a safe strategy to identify patients at low risk for acute myocardial injury and infarction.
The efficacy (proportion identified as low risk based on baseline hs-cTnT<6 ng/L) of identifying low-risk patients was examined in a multicenter (n=22 sites) US cohort study of emergency department patients undergoing at least 1 hs-cTnT (CV Data Mart Biomarker cohort). We then determined the performance of a single hs-cTnT<6 ng/L (biomarker alone) to exclude acute myocardial injury (subsequent hs-cTnT >99th percentile in those with an initial hs-cTnT<6 ng/L). The clinically intended rule-out strategy combining a nonischemic ECG with a baseline hs-cTnT<6 ng/L was subsequently tested in an adjudicated cohort in which the diagnostic performance for ruling out acute myocardial infarction and safety (myocardial infarction or death at 30 days) were evaluated.
A total of 85 610 patients were evaluated in the CV Data Mart Biomarker cohort, among which 24 646 (29%) had a baseline hs-cTnT<6 ng/L. Women were more likely than men to have hs-cTnT<6 ng/L (38% versus 20%, <0.0001). Among 11 962 patients with baseline hs-cTnT<6 ng/L and serial measurements, only 1.2% developed acute myocardial injury, resulting in a negative predictive value of 98.8% (95% CI, 98.6-99.0) and sensitivity of 99.6% (95% CI, 99.5-99.6). In the adjudicated cohort, a nonischemic ECG with hs-cTnT<6 ng/L identified 33% of patients (610/1849) as low risk and resulted in a negative predictive value and sensitivity of 100% and a 30-day rate of 0.2% for myocardial infarction or death.
A single hs-cTnT below the limit of quantitation of 6 ng/L is a safe and rapid method to identify a substantial number of patients at very low risk for acute myocardial injury and infarction.
有充分的数据支持使用单个高敏肌钙蛋白 T(hs-cTnT)低于检测限 5ng/L 来排除急性心肌梗死。根据美国食品和药物管理局的规定,hs-cTnT 只能报告至 6ng/L 的定量限,这一阈值的数据有限。我们的目标是确定 hs-cTnT 低于 6ng/L 的定量限是否是一种安全的策略,可以识别急性心肌损伤和梗死风险较低的患者。
在一项多中心(22 个地点)美国急诊科患者进行至少 1 次 hs-cTnT(CV Data Mart Biomarker 队列)的研究中,我们检测了基于基线 hs-cTnT<6ng/L 识别低危患者的功效(根据基线 hs-cTnT<6ng/L 确定为低危的患者比例)。然后,我们确定了单个 hs-cTnT<6ng/L(仅生物标志物)排除急性心肌损伤的性能(在初始 hs-cTnT<6ng/L 的患者中,随后的 hs-cTnT>99 百分位)。随后,在一个经过裁决的队列中测试了结合非缺血性心电图和基线 hs-cTnT<6ng/L 的临床预期排除策略,评估了排除急性心肌梗死的诊断性能和安全性(30 天内心肌梗死或死亡)。
在 CV Data Mart Biomarker 队列中评估了 85610 例患者,其中 24646 例(29%)基线 hs-cTnT<6ng/L。女性比男性更有可能 hs-cTnT<6ng/L(38%比 20%,<0.0001)。在 11962 例基线 hs-cTnT<6ng/L 且有连续测量值的患者中,仅有 1.2%发生急性心肌损伤,阴性预测值为 98.8%(95%CI,98.6-99.0),敏感性为 99.6%(95%CI,99.5-99.6)。在裁决队列中,非缺血性心电图结合 hs-cTnT<6ng/L 确定了 33%的患者(610/1849)为低危,阴性预测值和敏感性为 100%,30 天内心肌梗死或死亡发生率为 0.2%。
hs-cTnT 低于 6ng/L 的定量限是一种安全、快速的方法,可以识别出大量急性心肌损伤和梗死风险极低的患者。